In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wyeth-Ayerst's Strategic Retreat

Executive Summary

Premarin was the drug that would never die. With its patent long-since expired, Wyeth-Ayerst has nonetheless taken advantage of osteoporosis and other studies to promote the hormone-based drug to more than $800 million in worldwide sales. Now it’s co-promoting what my be its own worst enemy, Merck’s Fosamax. It could thereby profit from this important new drug and, by putting together a disease management program that incorporates both drugs, make an ally out of this competitor. Included is a chart of the industry's osteoporosis deals.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts